Nephrology

Imagination

EU CT Nummer:  2022-502102-32-00

Recruitment is open

 Evaluate the Efficacy And Safety Of Ro7434656, an Antisense Inhibitor Of Complement Factor B, in Patients with Primary Iga Nephropathy At High Risk of Progression

Objective

Safely slowing IgA nephropathy

We are looking for patients with:

  • primary IgA-nephrpathy

  •  eGFR ≥ 30 mL/min/1.73 m2

  • treated with ACE-Inhibitoren or ARBs

If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.

Contact